USD 1.76
| ticker | 1 day return % | 1 week return % | 1 month return % | 3 months return % | 6 months return % | 1 year return % | 3 years return % | 5 years return % | 10 years return % | maximum return % |
|---|---|---|---|---|---|---|---|---|---|---|
| ADCT | -3.8 | -2.2 | -10.2 | -44.8 | -51.6 | -7.4 | -88.6 | -94.1 | -94.1 | -94.1 |
| S&P 500 | 0.9 | 0.9 | 2.0 | 3.4 | 8.7 | 24.7 | 37.2 | 82.1 | 193.2 | 34153.9 |
Our interactive price chart includes various drawing tools to help you analyze the product more effectively. Below is a quick guide on how to use these tools: Full Guideline
Feel free to experiment with these tools to enhance your technical analysis. Remember, any drawings you make are temporary and will be lost upon refreshing the page unless saved as an image using the 'Camera' icon.
Get instant AI-powered professional insights on prices:
💡Generate AI Technical Analysis ReportA Multi-Interval Candlestick Chart displays the price movements of an asset over different time intervals. Each candlestick represents the open, high, low, and close prices for a specific interval. The chart can be used to identify trends and patterns in price movements.
| Attribute | Value |
|---|---|
| symbol | ADCT |
| name | ADC Therapeutics SA |
| price | 1.76 |
| changes percentage | -3.8251 |
| change | -0.07 |
| day low | 1.75 |
| day high | 1.87 |
| year high | 6.04 |
| year low | 1.675 |
| market cap | 170173696 |
| price avg 50 | 2.2388 |
| price avg 200 | 3.15745 |
| exchange | NYSE |
| volume | 489240 |
| avg volume | 917675 |
| open | 1.85 |
| previous close | 1.83 |
| eps | -2.39 |
| pe | -0.74 |
| earnings announcement | 2025-03-10T12:30:00.000+0000 |
| shares outstanding | 96689600 |
| timestamp | 2025-01-21 21:00:02 |
We derive the score of a company's financial statements by evaluating the weighted average sentiment across key within the statements. The cumulative score, normalized to a sum of 1, serves as a metric for assessing the company's performance during the specified period. A higher score indicates stronger performance. However, it's crucial to note that while this score provides valuable insights, it is just one of many factors to consider when making informed investment decisions. A holistic evaluation, considering various aspects of the company's financial health and market conditions, is essential for a well-rounded investment strategy.
| 2023 | 2022 | Y/Y change % | |
|---|---|---|---|
| 0001771910 | |||
| revenue | 69558000 | 209908000 | -66.86 |
| gross profit | 67029000 | 205329000 | -67.36 |
| gross profit ratio | 0.96 | 0.98 | -1.49 |
| research and development expenses | 127127000 | 187898000 | -32.34 |
| operating expenses | 233015000 | 328956000 | -29.17 |
| interest income | 10540000 | 17970000 | -41.35 |
| interest expense | 46325000 | 36924000 | 25.46 |
| ebitda | -146762000 | -108055000 | -35.82 |
| ebitdaratio | -2.11 | -0.47 | -348.11 |
| operating income | -165986000 | -123627000 | -34.26 |
| operating income ratio | -2.39 | -0.59 | -305.17 |
| net income | -240053000 | -155800000 | -54.08 |
| net income ratio | -3.45 | -0.74 | -364.97 |
| eps | -2.94 | -1.99 | -47.74 |
Revenue Growth: revenue increased to 70 million in 2023 from 210 million in 2022 representing a change of -66.86%. This indicates a sales growth, which is a positive sign for the company.
Operating Expenses: Operating Expenses decreased to 233 million in 2023 from 329 million in 2022 representing a change of -29.17%. The decrease in operating expenses can be attributed to various factors such as improved profitability, cost optimization and financial stability, lower operating expenses can be positive indicators.
EBITDA: EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) increased to -147 million in 2023 from -108 million in 2022 representing a change of -35.82%. The increase in EBITDA indicates improved operational efficiency and profitability.
Operating Income: Operating income increased to -166 million in 2023 from -124 million in 2022 representing a change of -34.26%. The increase in operating income indicates better operational performance and increased profitability.
Net Income: Net income increased to -240 million in 2023 from -156 million in 2022 representing a change of -54.08%. The increase in net income shows improved profitability and indicates that the company is generating more profit for each dollar of revenue.
Gross Profit: Gross Profit decreased to 67 million in 2023 from 205 million in 2022 representing a change of -67.36%. This indicates a sales profitability decline, which is a negative sign for the company.
Research and Development (R&D) Expenses: R&D Expenses decreased to 127 million in 2023 from 188 million in 2022 representing a change of -32.34%. This shows that the company decreased investment in innovation and product development, which is not a good sign for long-term growth.
Earnings per Share (EPS): EPS increased to -2.94 in 2023 from -2.94 in 2022 representing a change of -47.74%. This indicates that the company's earnings are decreasing and it is becoming less profitable on a per-share basis.
| 2024Q3 | 2024Q2 | Q/Q change % | |
|---|---|---|---|
| 0001771910 | |||
| revenue | 18016000 | 17410000 | 3.48 |
| gross profit | 17165000 | 15355000 | 11.79 |
| gross profit ratio | 0.95 | 0.88 | 8.03 |
| research and development expenses | 32502000 | 24295000 | 33.78 |
| operating expenses | 53177000 | 44396000 | 19.78 |
| interest income | 3438000 | 3253000 | 5.69 |
| interest expense | 13117000 | 12679000 | 3.45 |
| ebitda | -35564000 | -22516000 | -57.95 |
| ebitdaratio | -1.97 | -1.62 | -21.86 |
| operating income | -35564000 | -29041000 | -22.46 |
| operating income ratio | -1.97 | -1.67 | -18.34 |
| net income | -43969000 | -36544000 | -20.32 |
| net income ratio | -2.44 | -2.1 | -16.27 |
| eps | -0.42 | -0.38 | -10.53 |
Revenue Growth: revenue increased to 18 million in 2024Q3 from 17 million in 2024Q2 representing a change of 3.48%. This indicates a sales growth, which is a positive sign for the company.
Gross Profit: Gross Profit increased to 17 million in 2024Q3 from 15 million in 2024Q2 representing a change of 11.79%. This indicates a sales profitability growth, which is a positive sign for the company.
Research and Development (R&D) Expenses: R&D Expenses increased to 33 million in 2024Q3 from 24 million in 2024Q2 representing a change of 33.78%. This shows that the company continues to invest in innovation and product development, which is crucial for long-term growth.
EBITDA: EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) increased to -36 million in 2024Q3 from -23 million in 2024Q2 representing a change of -57.95%. The increase in EBITDA indicates improved operational efficiency and profitability.
Operating Income: Operating income increased to -36 million in 2024Q3 from -29 million in 2024Q2 representing a change of -22.46%. The increase in operating income indicates better operational performance and increased profitability.
Net Income: Net income increased to -44 million in 2024Q3 from -37 million in 2024Q2 representing a change of -20.32%. The increase in net income shows improved profitability and indicates that the company is generating more profit for each dollar of revenue.
Operating Expenses: Operating Expenses increased to 53 million in 2024Q3 from 44 million in 2024Q2 representing a change of 19.78%. The increase in operating expenses can be attributed to various factors such as marketing, administrative costs, and investments in infrastructure. It's important to monitor if these expenses are growing at a sustainable rate compared to revenue.
Earnings per Share (EPS): EPS increased to -0.42 in 2024Q3 from -0.42 in 2024Q2 representing a change of -10.53%. This indicates that the company's earnings are decreasing and it is becoming less profitable on a per-share basis.
| 2023 | 2022 | Y/Y change % | |
|---|---|---|---|
| 0001771910 | |||
| total assets | 354782000 | 529168000 | -32.95 |
| total liabilities | 503031000 | 440441000 | 14.21 |
| total equity | -148249000 | 88727000 | -267.08 |
| cash and cash equivalents | 278598000 | 326441000 | -14.66 |
| short term investments | 0 | 0 | NaN |
| long term investments | 1647000 | 31152000 | -94.71 |
| total current assets | 336291000 | 446015000 | -24.60 |
| total non current assets | 18491000 | 83153000 | -77.76 |
| total current liabilities | 67670000 | 98957000 | -31.62 |
| total non current liabilities | 435361000 | 341484000 | 27.49 |
| common stock | 7312000 | 7312000 | 0.00 |
| retained earnings | -1335472000 | -1080685000 | -23.58 |
| total debt | 124377000 | 117375000 | 5.97 |
Total Assets: Total Assets decreased to 355 million in 2023 from 529 million in 2022 representing a change of -32.95%. Suggesting a decrease in asset holdings.
Total Liabilities: Total Liabilities increased to 503 million in 2023 from 440 million in 2022 representing a change of 14.21%. This indicates an increase in overall liabilities.
Total Equity: Total Equity decreased to -148 million in 2023 from 89 million in 2022 representing a change of -267.08%. This indicates a decrease in shareholders' equity.
Cash And Cash Equivalents: Cash And Cash Equivalents decreased to 279 million in 2023 from 326 million in 2022 representing a change of -14.66%. This indicates a decrease in available liquid assets.
Total Current Assets: Total Current Assets decreased to 336 million in 2023 from 446 million in 2022 representing a change of -24.6%. This indicates a worsen liquidity position.
Retained Earnings: Retained Earnings decreased to -1,335 million in 2023 from -1,081 million in 2022 representing a change of -23.58%. This indicates an accumulated losses.
Total Debt: Total Debt increased to 124 million in 2023 from 117 million in 2022 representing a change of 5.97%. This indicates an increase in overall debt burden.
Total Current Liabilities: Total Current Liabilities decreased to 68 million in 2023 from 99 million in 2022 representing a change of -31.62%. This indicates a lower short-term debt burden.
| 2024Q3 | 2024Q2 | Q/Q change % | |
|---|---|---|---|
| 0001771910 | |||
| total assets | 349079000 | 371779000 | -6.11 |
| total liabilities | 521025000 | 503449000 | 3.49 |
| total equity | -171946000 | -131669999 | -30.59 |
| cash and cash equivalents | 274272000 | 300119000 | -8.61 |
| short term investments | 0 | 0 | NaN |
| long term investments | 0 | 260000 | -100.00 |
| total current assets | 333005000 | 355359000 | -6.29 |
| total non current assets | 16074000 | 16420000 | -2.11 |
| total current liabilities | 67679000 | 57632000 | 17.43 |
| total non current liabilities | 453346000 | 445817000 | 1.69 |
| common stock | 8233000 | 8233000 | 0.00 |
| retained earnings | -1462591000 | -1418622000 | -3.10 |
| total debt | 331508000 | 124397000 | 166.49 |
Total Assets: Total Assets decreased to 349 million in 2024Q3 from 372 million in 2024Q2 representing a change of -6.11%. Suggesting a decrease in asset holdings.
Total Liabilities: Total Liabilities increased to 521 million in 2024Q3 from 503 million in 2024Q2 representing a change of 3.49%. This indicates an increase in overall liabilities.
Total Equity: Total Equity decreased to -172 million in 2024Q3 from -132 million in 2024Q2 representing a change of -30.59%. This indicates a decrease in shareholders' equity.
Cash And Cash Equivalents: Cash And Cash Equivalents decreased to 274 million in 2024Q3 from 300 million in 2024Q2 representing a change of -8.61%. This indicates a decrease in available liquid assets.
Total Current Assets: Total Current Assets decreased to 333 million in 2024Q3 from 355 million in 2024Q2 representing a change of -6.29%. This indicates a worsen liquidity position.
Total Current Liabilities: Total Current Liabilities increased to 68 million in 2024Q3 from 58 million in 2024Q2 representing a change of 17.43%. This indicates a higher short-term debt burden.
Retained Earnings: Retained Earnings decreased to -1,463 million in 2024Q3 from -1,419 million in 2024Q2 representing a change of -3.1%. This indicates an accumulated losses.
Total Debt: Total Debt increased to 332 million in 2024Q3 from 124 million in 2024Q2 representing a change of 166.49%. This indicates an increase in overall debt burden.
| 2023 | 2022 | Y/Y change % | |
|---|---|---|---|
| 0001771910 | |||
| net change in cash | -47843000 | -140103000 | 65.85 |
| operating cash flow | -118686000 | -136794000 | 13.24 |
| free cash flow | -121902000 | -139092000 | 12.36 |
| capital expenditure | -3216000 | -2298000 | -39.95 |
| depreciation and amortization | 3267000 | 2328000 | 40.34 |
| deferred income tax | 37104000 | -708000 | 5340.68 |
| stock based compensation | 13495000 | 49322000 | -72.64 |
| accounts payables | 3173000 | 310000 | 923.55 |
| inventory | 1608000 | -8964000 | 117.94 |
| acquisitions net | 0 | 0 | NaN |
| investments in property plant and equipment | -3216000 | -2298000 | -39.95 |
| net cash used for investing activites | -3216000 | -2508000 | -28.23 |
| debt repayment | 0 | -2707000 | 100.00 |
| common stock issued | 773000 | 6130000 | -87.39 |
| common stock repurchased | 0 | -221000 | 100.00 |
| dividends paid | 0 | 0 | NaN |
| net cash used provided by financing activities | 73875000 | -593000 | 12557.84 |
| cash at end of period | 278598000 | 326441000 | -14.66 |
| accounts receivables | 47789000 | -42753000 | 211.78 |
| cash at beginning of period | 326441000 | 466544000 | -30.03 |
Net Change in Cash: Net Change in Cash increased to -48 million in 2023 from -140 million in 2022 representing a change of 65.85%. Indicating an increased ability to generate cash from the company's operations or its cash flow position.
Operating Cash Flow: Operating Cash Flow increased to -119 million in 2023 from -137 million in 2022 representing a change of 13.24%. This indicates that the company generated more cash from its core business operations.
Free Cash Flow: Free Cash Flow increased to -122 million in 2023 from -139 million in 2022 representing a change of 12.36%. This indicates an increase in cash generated after accounting for capital expenditures.
Capital Expenditure: Capital Expenditure decreased to -3 million in 2023 from -2 million in 2022 representing a change of -39.95%. This indicates a possible improved efficiency or a shift in the company's strategic priorities.
Stock-Based Compensation: Stock-Based Compensation decreased to 13 million in 2023 from 49 million in 2022 representing a change of -72.64%. This indicates decreased expenses, which is generally considered a positive sign from a financial perspective.
Deferred Income Tax: Deferred Income Tax increased to 37 million in 2023 from -1 million in 2022 representing a change of 5340.68%. This indicates that the company's tax liability for future periods has increased.
Accounts Payables: The absolute value of Accounts Payables increased to 3 million in 2023 from 0 million in 2022 representing a change of 923.55%. This indicates that the company has increased its outstanding obligations to its suppliers.
Accounts Receivables: Accounts Receivables increased to 48 in 2023 from -43 million in 2022 representing a change of 211.78%. This suggests that the company is less capable of collecting payments from its customers.
| 2024Q3 | 2024Q2 | Q/Q change % | |
|---|---|---|---|
| 0001771910 | |||
| operating cash flow | -25043000 | -31583236 | 20.71 |
| free cash flow | -25259000 | -31604035 | 20.08 |
| capital expenditure | -216000 | -20799 | -938.51 |
| depreciation and amortization | 771000 | 838000 | -8.00 |
| deferred income tax | 0 | 0 | NaN |
| stock based compensation | 2806000 | 1988000 | 41.15 |
| accounts receivables | -1218051 | 281051 | -533.39 |
| accounts payables | 4766242 | -4736242 | 200.63 |
| inventory | 1085181 | 518819 | 109.16 |
| acquisitions net | 0 | 0 | NaN |
| investments in property plant and equipment | -225201 | -20799 | -982.75 |
| net cash used for investing activites | -225201 | -20799 | -982.75 |
| debt repayment | 0 | 0 | NaN |
| common stock issued | -1225000 | 97072598 | -101.26 |
| common stock repurchased | 0 | 0 | NaN |
| dividends paid | 0 | 0 | NaN |
| net cash used provided by financing activities | -879000 | 97072598 | -100.91 |
| net change in cash | -25847000 | 65834000 | -139.26 |
| cash at end of period | 274272000 | 300119000 | -8.61 |
| cash at beginning of period | 300119000 | 234285000 | 28.10 |
Net Change in Cash: Net Change in Cash decreased to -26 million in 2024Q3 from 66 million in 2024Q2 representing a change of -139.26%. Indicating a declined ability to generate cash from the company's operations or its cash flow position.
Stock-Based Compensation: Stock-Based Compensation increased to 3 million in 2024Q3 from 2 million in 2024Q2 representing a change of 41.15%. This indicates increased expenses, which is generally considered a negative sign from a financial perspective.
Accounts Payables: The absolute value of Accounts Payables increased to 5 million in 2024Q3 from 5 million in 2024Q2 representing a change of 200.63%. This indicates that the company has increased its outstanding obligations to its suppliers.
Operating Cash Flow: Operating Cash Flow increased to -25 million in 2024Q3 from -32 million in 2024Q2 representing a change of 20.71%. This indicates that the company generated more cash from its core business operations.
Free Cash Flow: Free Cash Flow increased to -25 million in 2024Q3 from -32 million in 2024Q2 representing a change of 20.08%. This indicates an increase in cash generated after accounting for capital expenditures.
Capital Expenditure: Capital Expenditure decreased to 0 million in 2024Q3 from 0 million in 2024Q2 representing a change of -938.51%. This indicates a possible improved efficiency or a shift in the company's strategic priorities.
Accounts Receivables: Accounts Receivables decreased to -1 million in 2024Q3 from 0 million in 2024Q2 representing a change of -533.39%. This suggests that the company has been able to collect payments from its customers more efficiently and timely.
We save you time by utilizing Generative AI to summarize earnings transcripts. Our summaries provide a clear insight into the company's current performance, future outlook, and overall sentiment expressed during the call. Click on below links to explore more.
Note: The years mentioned below are fiscal years in accounting.
Q3 2024 Earnings call transcript
EPS represents the portion of a company's profit allocated to each outstanding share of common stock. A higher EPS is generally favorable, indicating stronger profitability on a per-share basis.
Positive EPS: A positive EPS signifies that a company is profitable, it is generally viewed positively, supporting stock value and investor confidence.
Negative EPS: Indicates that a company is operating at a loss, which could lead to negative sentiment, potential stock depreciation, and concerns about the company's financial health.
The Next Earning Date represents when the company plans to release its next set of financial results.
An upward trend in EPS suggests consistent growth in earnings, often leading to increased investor confidence. A downward trend may indicate a decline in earnings, potentially decreasing investor confidence and stock value. Fluctuating EPS suggests unpredictable financial performance, warranting cautious investor analysis.
Earnings surprise occurs when a company's actual earnings differ from analysts' expectations. A positive earnings surprise typically reflects better-than-expected performance, potentially leading to stock appreciation. Conversely, a negative earnings surprise can result in stock depreciation. An earnings surprise of zero means the earnings met expectations, which typically has a neutral impact on stock price.
Discover detailed analyst recommendations for stocks, including categories such as Buy, Hold, Sell, Strong Buy, and Strong Sell. These insights are based on thorough analysis of financial and market factors. The consensus is calculated by assigning a numerical score to each recommendation. These scores are then weighted and averaged over a specified period to provide a comprehensive view of the stock's outlook, with the final score determining the overall consensus.
| 2023-12-31 | 2022-12-31 | Y/Y change % | |
|---|---|---|---|
| FY | |||
| calendar year | 2023 | 2022 | NaN |
| revenue per share | 0.85 | 2.69 | -68.31 |
| net income per share | -2.94 | -1.99 | -47.37 |
| operating cash flow per share | -1.45 | -1.75 | 17.02 |
| free cash flow per share | -1.49 | -1.78 | 16.18 |
| cash per share | 3.41 | 4.18 | -18.37 |
| book value per share | -1.81 | 1.14 | -259.81 |
| tangible book value per share | -1.81 | 0.95 | -290.66 |
| shareholders equity per share | -1.81 | 1.14 | -259.81 |
| interest debt per share | 2.09 | 1.97 | 5.81 |
| market cap | 135642195.56 | 300107381.76 | -54.80 |
| enterprise value | -18578804.44 | 91041381.76 | -120.41 |
| pe ratio | -0.57 | -1.93 | 70.67 |
| price to sales ratio | 1.95 | 1.43 | 36.40 |
| pocfratio | -1.14 | -2.19 | 47.91 |
| pfcf ratio | -1.11 | -2.16 | 48.43 |
| pb ratio | -0.91 | 3.38 | -127.05 |
| ptb ratio | -0.91 | 3.38 | -127.05 |
| ev to sales | -0.27 | 0.43 | -161.58 |
| enterprise value over ebitda | 0.13 | -0.84 | 115.02 |
| ev to operating cash flow | 0.16 | -0.67 | 123.52 |
| ev to free cash flow | 0.15 | -0.65 | 123.28 |
| earnings yield | -1.77 | -0.52 | -240.90 |
| free cash flow yield | -0.9 | -0.46 | -93.91 |
| debt to equity | -0.84 | 1.32 | -163.42 |
| debt to assets | 0.35 | 0.22 | 58.05 |
| net debt to ebitda | 1.05 | 1.93 | -45.69 |
| current ratio | 4.97 | 4.51 | 10.26 |
| interest coverage | -3.58 | -3.35 | -7.02 |
| income quality | 0.49 | 0.88 | -43.69 |
| dividend yield | 0 | 0 | NaN |
| payout ratio | 0 | 0 | NaN |
| sales general and administrative to revenue | 0.7 | 0.67 | 3.60 |
| research and ddevelopement to revenue | 1.83 | 0.9 | 104.17 |
| intangibles to total assets | 0 | 0.03 | -100.00 |
| capex to operating cash flow | -0.03 | -0.02 | -61.30 |
| capex to revenue | 0.05 | 0.01 | 322.33 |
| capex to depreciation | 0.98 | 0.99 | -0.28 |
| stock based compensation to revenue | 0.19 | 0.23 | -17.43 |
| graham number | 10.95 | 7.14 | 53.46 |
| roic | -0.69 | -0.29 | -139.07 |
| return on tangible assets | -0.68 | -0.3 | -123.58 |
| graham net net | -2.42 | -0.64 | -277.79 |
| working capital | 268621000 | 347058000 | -22.60 |
| tangible asset value | -148249000 | 74367000 | -299.35 |
| net current asset value | -166740000 | 5574000 | -3091.39 |
| invested capital | 284754000 | 371399000 | -23.33 |
| average receivables | 49076500 | 51594500 | -4.88 |
| average payables | 13960000 | 12215500 | 14.28 |
| average inventory | 17370500 | 14843000 | 17.03 |
| days sales outstanding | 132.14 | 126.89 | 4.14 |
| days payables outstanding | 2247.01 | 984.52 | 128.23 |
| days of inventory on hand | 2334.76 | 1479.77 | 57.78 |
| receivables turnover | 2.76 | 2.88 | -3.98 |
| payables turnover | 0.16 | 0.37 | -56.19 |
| inventory turnover | 0.16 | 0.25 | -36.62 |
| roe | 1.62 | -1.76 | 192.22 |
| capex per share | 0.04 | 0.03 | 33.85 |
ROE: Return on Equity (ROE) increased to 1.62 on 2023-12-31 from -1.76 on 2022-12-31, representing a change of 192.22%. Suggesting the company has been generating high returns for its shareholders.
PE Ratio: Price-to-Earnings (P/E) Ratio increased to -0.57 on 2023-12-31 from -1.93 on 2022-12-31, representing a change of 70.67%. Indicating an increase in the relative valuation of the company's stock.
Debt-to-Equity Ratio: Debt-to-Equity Ratio decreased to -0.84 on 2023-12-31 from 1.32 on 2022-12-31, representing a change of -163.42%. The debt-to-equity ratio has been decreasing, indicating that the company has been relying less on debt financing. A ratio of 1 or below is often considered healthy and indicates that the company's total debt is equal to or less than its total equity.
Current Ratio: Current Ratio increased to 4.97 on 2023-12-31 from 4.51 on 2022-12-31, representing a change of 10.26%. The current ratio has been increasing, suggesting an increase in the company's short-term liquidity. Since it's above 3, indicating poor management of working capital.
| 2024-09-30 Q3 | 2024-06-30 Q2 | Q/Q change % | |
|---|---|---|---|
| ADCT | |||
| calendar year | 2024 | 2024 | NaN |
| revenue per share | 0.17 | 0.18 | -5.54 |
| net income per share | -0.42 | -0.38 | -9.83 |
| operating cash flow per share | -0.24 | -0.33 | 27.62 |
| free cash flow per share | -0.24 | -0.33 | 27.04 |
| cash per share | 2.62 | 3.14 | -16.58 |
| book value per share | -1.64 | -1.38 | -19.21 |
| tangible book value per share | -1.64 | -1.38 | -19.21 |
| shareholders equity per share | -1.64 | -1.38 | -19.21 |
| interest debt per share | 3.29 | 1.43 | 129.51 |
| market cap | 330198362.55 | 352143781.6 | -6.23 |
| enterprise value | 387434362.55 | 176421781.6 | 119.61 |
| pe ratio | -1.88 | -2.41 | 22.07 |
| price to sales ratio | 18.33 | 20.23 | -9.39 |
| pocfratio | -13.19 | -11.15 | -18.26 |
| pfcf ratio | -13.07 | -11.14 | -17.32 |
| pb ratio | -1.92 | -2.67 | 28.20 |
| ptb ratio | -1.92 | -2.67 | 28.20 |
| ev to sales | 21.51 | 10.13 | 112.22 |
| enterprise value over ebitda | -10.89 | -7.84 | -39.04 |
| ev to operating cash flow | -15.47 | -5.59 | -176.96 |
| ev to free cash flow | -15.34 | -5.58 | -174.77 |
| earnings yield | -0.13 | -0.1 | -28.31 |
| free cash flow yield | -0.08 | -0.09 | 14.76 |
| debt to equity | -1.93 | -0.94 | -104.07 |
| debt to assets | 0.95 | 0.33 | 183.82 |
| net debt to ebitda | -1.61 | 7.8 | -120.62 |
| current ratio | 4.92 | 6.17 | -20.20 |
| interest coverage | -2.71 | -2.29 | -18.37 |
| income quality | 0.57 | 0.86 | -34.10 |
| dividend yield | 0 | 0 | NaN |
| payout ratio | 0 | 0 | NaN |
| sales general and administrative to revenue | 0.87 | 0.92 | -6.19 |
| research and ddevelopement to revenue | 1.8 | 1.4 | 29.28 |
| intangibles to total assets | 0 | 0 | NaN |
| capex to operating cash flow | -0.01 | -0.0 | -1209.73 |
| capex to revenue | 0.01 | 0.0 | 903.58 |
| capex to depreciation | 0.28 | 0.02 | 1028.76 |
| stock based compensation to revenue | 0.16 | 0.11 | 36.40 |
| graham number | 3.93 | 3.44 | 14.43 |
| roic | -0.13 | -0.09 | -37.94 |
| return on tangible assets | -0.13 | -0.1 | -28.14 |
| graham net net | -2.11 | -1.87 | -12.81 |
| working capital | 265326000 | 297727000 | -10.88 |
| tangible asset value | -171946000 | -131670000 | -30.59 |
| net current asset value | -188020000 | -148090000 | -26.96 |
| invested capital | 280235000 | 312895000 | -10.44 |
| average receivables | 23449000 | 23027000 | 1.83 |
| average payables | 12540000 | 12511500 | 0.23 |
| average inventory | 15631500 | 15594000 | 0.24 |
| days sales outstanding | 120.04 | 118.21 | 1.55 |
| days payables outstanding | 1519.95 | 468.96 | 224.11 |
| days of inventory on hand | 1699.74 | 665.3 | 155.49 |
| receivables turnover | 0.75 | 0.76 | -1.52 |
| payables turnover | 0.06 | 0.19 | -69.15 |
| inventory turnover | 0.05 | 0.14 | -60.86 |
| roe | 0.26 | 0.28 | -7.86 |
| capex per share | 0.0 | 0.0 | 848.02 |
ROE: Return on Equity (ROE) decreased to 0.26 on 2024-09-30 Q3 from 0.28 on 2024-06-30 Q2, representing a change of -7.86%. However, ROE is >= 15%, suggesting that the company has been generating high returns for its shareholders still.
PE Ratio: Price-to-Earnings (P/E) Ratio increased to -1.88 on 2024-09-30 Q3 from -2.41 on 2024-06-30 Q2, representing a change of 22.07%. Indicating an increase in the relative valuation of the company's stock.
Debt-to-Equity Ratio: Debt-to-Equity Ratio decreased to -1.93 on 2024-09-30 Q3 from -0.94 on 2024-06-30 Q2, representing a change of -104.07%. The debt-to-equity ratio has been decreasing, indicating that the company has been relying less on debt financing. A ratio of 1 or below is often considered healthy and indicates that the company's total debt is equal to or less than its total equity.
Current Ratio: Current Ratio decreased to 4.92 on 2024-09-30 Q3 from 6.17 on 2024-06-30 Q2, representing a change of -20.20%. The current ratio has been declining, suggesting a decrease in the company's short-term liquidity. Since it's above 3, indicating poor management of working capital.
Negative Sentiment: Discounted Cash Flow value is 0.29 which is lower than current price 1.76, indicates the company may be overvalued.
| Market Capitalization | Enterprise Value | |
|---|---|---|
| Definition | The total market value of a company's outstanding shares | The total market value of a company, including its debt and other liabilities |
| Calculation | Current share price * Total number of outstanding shares | Market capitalization + Total debt - Cash and cash equivalents |
| Focus | Equity component of a company's value | Total economic value of a company |
| Usefulness | Assesses a company's size and growth potential based on investor sentiment | Provides a more comprehensive valuation that considers both equity and debt |
Analyzing dividends is a crucial aspect of investment evaluation, offering valuable insights into a company's financial health and its commitment to shareholder returns. Dividends represent a portion of a company's profits distributed to its shareholders, providing a steady income stream. We help you analyze dividends based on the indicators mentioned below:
• Investors often assess the average dividend amount, observing trends over time to gauge the company's stability and growth potential. A positive trend in average dividends indicates a consistent and potentially lucrative investment. Additionally, evaluating the trend of dividend increases provides insight into the company's financial strength and management's confidence in future earnings.
• Consistency in paying dividends is a reassuring sign, reflecting a company's reliability and commitment to shareholder value. For investors, dividends not only offer income but also contribute to the overall total return on investment.
• Companies with a history of regular and increasing dividends can attract income-focused investors seeking stable returns, making dividends a critical factor in building a well-rounded investment portfolio.
Interested in the overall sentiment for a particular period? Check out our news sentiment analysis tool.
Sentiment: Positive
Publish Date: 2025-01-02 16:05:00
LAUSANNE, Switzerland , Jan. 2, 2025 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced that the Company has made grants of options to purchase an aggregate of 20,000 of the Company's common shares to two new employees on January 2, 2025 (each, a "Grant"). The Grants were offered as material inducement to the employees' employment.
Sentiment: Positive
Publish Date: 2024-12-30 16:30:00
LAUSANNE, Switzerland , Dec. 30, 2024 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced the completion of enrollment in LOTIS-5, the Phase 3 confirmatory trial evaluating ZYNLONTA® (loncastuximab tesirine-lpyl) in combination with rituximab (Lonca-R) in patients with relapsed or refractory diffuse large B-cell lymphoma (r/r DLBCL). ZYNLONTA previously received accelerated approval for the treatment of r/r DLBCL after two or more lines of systemic therapy from the FDA in 2021.
Sentiment: Positive
Publish Date: 2024-12-12 14:03:49
Initial positive results released from the phase 1b study, using ZYNLONTA + COLUMVI for the treatment of patients with 2nd-line relapsed/refractory DLBCL. Additional results from the phase 1b study, using ZYNLONTA + COLUMVI for the treatment of patients with 2nd-line relapsed/refractory DLBCL, to be released in the 1st half of 2025. The seven major Diffuse Large B-cell Lymphoma markets are expected to reach $5.25 billion by 2034.
Sentiment: Positive
Publish Date: 2024-12-11 07:30:00
ZYNLONTA in combination with glofitamab demonstrated clinically meaningful benefit with 94% best ORR and 72% CR rate Safety data show no dose-limiting toxicities (DLTs), no high-grade cytokine release syndrome (CRS) or high-grade immune effector cell-associated neurotoxicity syndrome (ICANS) across all patients Company to host conference call today at 8:30 a.m. EST LAUSANNE, Switzerland , Dec. 11, 2024 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced positive initial data from the LOTIS-7 Phase 1b open-label clinical trial evaluating the safety and efficacy of ZYNLONTA® in combination with the bispecific antibody glofitamab (COLUMVI™) in patients with relapsed or refractory diffuse large B-cell lymphoma (r/r DLBCL).
Sentiment: Positive
Publish Date: 2024-12-09 07:30:00
Publication follows oral presentation at the American Society of Hematology (ASH) Annual Meeting Combination in r/r follicular lymphoma shows best ORR of 97% and CR rate of 77% with 12-month PFS of 95% Additional IIT data also presented at ASH on ZYNLONTA monotherapy in marginal zone lymphoma shows ORR of 91% and 70% CR LAUSANNE, Switzerland , Dec. 9, 2024 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced updated data from the investigator-initiated Phase 2 clinical trial evaluating ZYNLONTA® (loncastuximab tesirine-lpyl) in combination with rituximab to treat relapsed or refractory (r/r) follicular lymphoma (FL) were published in the December issue of The Lancet Haematology, following an oral presentation of the data at the recent 66th American Society of Hematology (ASH) Annual Meeting and Exposition. "We are excited by the publication of these results in The Lancet Haematology demonstrating ZYNLONTA's robust clinical activity in follicular lymphoma, particularly in patients classified as high-risk POD24 and those with high tumor burden where there remains significant unmet need," said Mohamed Zaki, MD, PhD, Chief Medical Officer of ADC Therapeutics.
Sentiment: Positive
Publish Date: 2024-12-06 07:30:00
Company to host corporate update webcast to share results on December 11, 2024 LAUSANNE, Switzerland , Dec. 6, 2024 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), today announced that it will host a conference call and live webcast on Wednesday, December 11, 2024, at 8:30 a.m. EST to provide an update on preliminary data from the LOTIS-7 Phase 1b open-label clinical trial evaluating the safety and efficacy of ZYNLONTA® in combination with the bispecific antibody glofitamab (COLUMVI™) in patients with relapsed or refractory diffuse large B-cell lymphoma (r/r DLBCL).
Sentiment: Positive
Publish Date: 2024-12-02 16:30:00
LAUSANNE, Switzerland , Dec. 2, 2024 /PRNewswire/ --Â ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced that the Company has made grants of options to purchase an aggregate of 34,900 of the Company's common shares to three new employees on December 2, 2024 (each, a "Grant"). The Grants were offered as material inducement to the employees' employment.
Sentiment: Positive
Publish Date: 2024-11-09 11:01:03
ADC Therapeutics SA (NYSE:ADCT ) Q3 2024 Results Conference Call November 7, 2024 8:30 AM ET Company Participants Marcy Graham - Investor Relations Ameet Mallik - Chief Executive Officer Pepe Carmona - Chief Financial Officer Lindsay Drucker Mann - Global Chief Financial Officer Conference Call Participants Michael Schmidt - Guggenheim Eric Schmidt - Cantor Fitzgerald Kelly Shi - Jefferies Operator Good morning, ladies and gentlemen, and welcome to the ADC Therapeutics Third Quarter 2024 Earnings Conference Call. [Operator Instructions] This call is being recorded on Thursday, November 7, 2024.
Sentiment: Positive
Publish Date: 2024-11-08 13:14:13
ADC Therapeutics Faces Competitive Oncology Market But Analyst Sees 100% Upside – Here's Why
Sentiment: Negative
Publish Date: 2024-11-07 09:50:33
ADC Therapeutics SA (ADCT) came out with a quarterly loss of $0.42 per share versus the Zacks Consensus Estimate of a loss of $0.36. This compares to loss of $0.58 per share a year ago.
Sentiment: Positive
Publish Date: 2024-11-07 07:30:00
LOTIS-5 full enrollment and LOTIS-7 initial efficacy, safety update anticipated by end of 2024 Updated ZYNLONTA® Phase 2 IIT data in indolent lymphomas to be presented at the 66th American Society of Hematology Annual Meeting in December 2024 Discontinuing ADCT-601 program and prioritizing exatecan-based platform for solid tumors Company to host conference call today at 8:30 a.m. EST LAUSANNE, Switzerland , Nov. 7, 2024 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today reported financial results for the third quarter ended September 30, 2024, and provided recent operational updates.
Sentiment: Positive
Publish Date: 2024-11-05 09:47:00
Oral presentation of investigator-initiated Phase 2 study evaluating ZYNLONTA® (loncastuximab tesirine-lpyl) in combination with rituximab in patients with r/r follicular lymphoma Poster presentation of first interim futility analysis of ongoing investigator-initiated Phase 2 clinical trial studying ZYNLONTA as treatment for r/r marginal zone lymphoma LAUSANNE, Switzerland , Nov. 5, 2024 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced independent, investigator-initiated study abstracts on ZYNLONTA® (loncastuximab tesirine-lpyl) have been accepted for presentation at the 66th American Society of Hematology (ASH) Annual Meeting, which will be held in San Diego, California from December 7-10, 2024. "Data from the abstract on the Phase 2 study of ZYNLONTA combined with rituximab in patients with high-risk relapsed or refractory follicular lymphoma demonstrated a robust response among the 35 evaluable patients, with an overall response rate at week 12 of 97.1%," said Mohamed Zaki, MD, PhD, Chief Medical Officer of ADC Therapeutics.
Sentiment: Positive
Publish Date: 2024-11-04 07:15:00
LAUSANNE, Switzerland , Nov. 4, 2024 /PRNewswire/ --Â ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced participation in two investor conferences in November: Guggenheim Securities Healthcare Innovation Conference Date: November 11, 2024 Presentation Time: 11:00 a.m. ET Format: Fireside ChatSpeaker: Ameet Mallik, Chief Executive Officer Jefferies London Healthcare Conference Date: November 19, 2024 Presentation Time: 11:00 a.m.
Sentiment: Positive
Publish Date: 2024-11-01 16:05:00
LAUSANNE, Switzerland , Nov. 1, 2024 /PRNewswire/ --Â ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced that the Company has made grants of options to purchase an aggregate of 42,000 of the Company's common shares to two new employees on November 1, 2024 (each, a "Grant"). The Grants were offered as material inducement to the employees' employment.
Sentiment: Neutral
Publish Date: 2024-11-01 10:41:17
Here is how ADC Therapeutics SA (ADCT) and Agios Pharmaceuticals (AGIO) have performed compared to their sector so far this year.
Sentiment: Neutral
Publish Date: 2024-10-31 07:15:00
LAUSANNE, Switzerland , Oct. 31, 2024 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced that it will host a conference call and live webcast on Thursday, November 7, 2024, at 8:30 a.m. EST to report financial results for the third quarter 2024 and provide operational updates.
* The sentiment analysis presented is generated through an algorithm and may be subject to inaccuracies. Users are advised to corroborate key information and employ further analytical methods prior to making critical decisions.
Get instant AI-powered professional insights:
💡Generate AI Technical Analysis ReportUnderstand the chart below:
Interpret Technical Indicators
| Indicator | Bullish | Bearish |
|---|---|---|
| Price and EMA ⓘ | Price crosses above EMA | Price crosses below EMA |
| Short-Term vs Long-Term EMA ⓘ | Short EMA crosses above Long EMA | Short EMA crosses below Long EMA |
| Volume ⓘ | Increasing volume during price uptrend | Increasing volume during price downtrend |
| MACD ⓘ | MACD crosses above Signal Line | MACD crosses below Signal Line |
| RSI ⓘ | RSI is below 30 (oversold) and starts to rise above 30 | RSI is above 70 (overbought) and starts to decline below 70 |
| Candlestick Patterns ⓘ | Bullish candlestick patterns | Bearish candlestick patterns |
Copyright © 2024 Sirius Investors
All rights reserved
